Assembly Biosciences Inc (ASMB):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8009)
◆英語タイトル:Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8009
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:39
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that develops, discovers, and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as microbiotic therapies for Clostridium difficile (C. difficile) infections (CDI) and chronic hepatitis B virus (HBV). It also develops Gemicel platform technology that helps for targeted oral delivery vaccines, small molecules, live biotherapeutics, and complex macromolecules that are aimed for specific region in gastrointestinal tract (GI). Assembly’s HBV Cure program target’s the chronic hepatitis B virus infection. The company owns and operates its research and development facilities located in Indiana, New York, and California, the US. Assembly is headquartered in Carmel, Indiana, the US.

Assembly Biosciences Inc (ASMB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Merger 10
Ventrus Biosciences Completes Merger with Assembly Pharma 10
Licensing Agreements 11
Allergan Enters into Licensing Agreement with Assembly Biosciences 11
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 13
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 14
Assembly Pharma Enters into Licensing Agreement with IURTC 15
Equity Offering 16
Assembly Biosciences Raises USD165.6 Million in Public Offering of Shares 16
Assembly Biosciences Plans to Raise up to USD250 Million in Public Offering of Securities 18
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 19
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 20
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 22
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 23
Ventrus Biosciences Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 24
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 26
Assembly Biosciences Inc – Key Competitors 27
Assembly Biosciences Inc – Key Employees 28
Assembly Biosciences Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 08, 2018: Assembly Biosciences announces second quarter 2018 financial results 30
May 07, 2018: Assembly Biosciences Reports First Quarter 2018 Financial Results 32
Corporate Communications 33
Apr 02, 2018: Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome 33
Mar 12, 2018: Assembly Biosciences Announces Additions to Management Team and Board of Directors 34
Dec 18, 2017: Assembly Biosciences Appoints Sue Mahony, PhD to Board of Directors 36
Jul 28, 2017: Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 37
Clinical Trials 38
Sep 25, 2017: Assembly Biosciences Selects Next-Generation CpAM Candidate for Advancement into Clinical Development 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Assembly Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ventrus Biosciences Completes Merger with Assembly Pharma 10
Allergan Enters into Licensing Agreement with Assembly Biosciences 11
Ventrus Biosciences Enters into Licensing Agreement with Therabiome 13
Assembly Biosciences Enters Into Licensing Agreement with Indiana University Research and Technology 14
Assembly Pharma Enters into Licensing Agreement with IURTC 15
Assembly Biosciences Raises USD165.6 Million in Public Offering of Shares 16
Assembly Biosciences Plans to Raise up to USD250 Million in Public Offering of Securities 18
Assembly Biosciences Prices Public Offering of Shares for USD60.2 Million 19
Assembly Biosciences Completes Underwriters Exercise of Over-Allotment of Public Offering of Shares 20
Assembly Biosciences Raises USD15.8 million in Private Placement of Shares 22
Ventrus Biosciences Announces Public Offering Of Shares For US$20.5 Million 23
Ventrus Biosciences Completes Underwriters' Exercise Of Over-Allotment Option For Public Offering Of Shares For US$16.7 Million 24
Ventrus Biosciences Completes Public Offering Of Preferred Shares For US$5.5 Million 26
Assembly Biosciences Inc, Key Competitors 27
Assembly Biosciences Inc, Key Employees 28
Assembly Biosciences Inc, Other Locations 29
Assembly Biosciences Inc, Subsidiaries 29

List of Figures
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Assembly Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Assembly Biosciences Inc (ASMB):製薬・医療:M&Aディール及び事業提携情報(Assembly Biosciences Inc (ASMB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆